With the global incidence of non-small cell lung cancer (NSCLC) on the rise, the
development of innovative treatment strategies is increasingly vital. This review underscores …

Tyrosine kinase inhibitor (TKI)‐targeted therapy has revolutionized cancer treatment by
selectively blocking specific signaling pathways crucial for tumor growth, offering improved …

Triple-negative breast cancer (TNBC)-the most aggressive and refractory subtype of breast
cancer-plagues many patients. The tumor physical microenvironment (TPME) is …

Based on the FLAURA and AURA III trials, compared to first-and second-generation
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), osimertinib …

Objective This study aimed to prospectively evaluate the efficacy and safety of anlotinib in
patients with platinum resistant/refractory ovarian cancer. Methods In this prospective, single …

目的: 探索抗血管生成药物安罗替尼联合吉非替尼一线用于治疗晚期EGFR 敏感突变的非小细胞
肺癌患者的临床效果和安全性. 方法: 选取2019 年5 月—2021 年2 月于连云港市第一人民医院 …

Early vascular-targeted drugs represented by VEGF single-pathway inhibitors pioneered the
idea of regulating the tumor growth microenvironment and enhanced the chemotherapy …

Primary bronchial lung cancer, referred to as lung cancer, is one of the malignant tumors
with high morbidity and mortality in China and other countries in the world, accounting for …

Editor's note: At present, EGFR-TKIs have significantly improved the treatment landscape of
patients with EGFR-sensitive mutations in advanced NSCLC, and EGFR-TKIs monotherapy …